|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||2.85 - 2.85|
|52-week range||2.85 - 2.85|
|Beta (5Y monthly)||1.80|
|PE ratio (TTM)||N/A|
|Earnings date||02 Mar 2022 - 07 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
CAMBRIDGE, Mass., January 10, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today provided an update on its clinical development programs and outlined its strategic priorities and upcoming expected milestones.
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
CAMBRIDGE, Mass., November 16, 2021--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in fireside chats at two upcoming virtual investor conferences. Management will also be available for one-on-one meetings.